Editas Medicine Q1 net loss $49M; cash $401.8M; EDIT-301 on track for 20 SCD patients by year-end

Editas Medicine, Inc.

2023-Q1 EPS reported -$0.71 revenue$9,851,000

Net loss $49.0M ($0.71 per share), vs $50.5M ($0.74) in Q1 2022; collaboration revenue $9.9M up from $6.8M.
Cash & equivalents $401.8M as of March 31, 2023; expected to fund operations into 2025.
19 SCD patients enrolled in EDIT-301 RUBY trial; on track to dose 20 total by year-end; clinical update at EHA June 2023.
First TDT patient dosed in EDITHAL trial with successful neutrophil and platelet engraftment; data expected by year-end.
Appointed Emma Reeve as Board Chair and Elliott Levy as independent director; sold iNK programs to Shoreline Biosciences.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Editas Medicine, Inc. reported the first quarter 2023 results: net income net loss attributable to common stockholders was $49.0 million, or $0.71 per share, EPS $0.71 per share.

Period: the first quarter 2023
Net income: net loss attributable to common stockholders was $49.0 million, or $0.71 per share
EPS: $0.71 per share
Result: reported results

Exact text from the filing

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023.

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.